Simcere Pharmaceutical Group (HKG:2096) said its new drug application (NDA) for its anti-influenza drug was accepted by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.
The drug is developed in partnership with Jiaxing AnDiCon Biotech. A Single tablet of the drug known as Jiaxing AnDiCon Biotech stops the virus replication within 24 hours. The medication is also useful in children under 12, the filing added.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。